Elevation of serum creatine kinase B-subunit levels by radiographic contrast agents in patients with neurologic disorders.
The effect of radiographic contrast agents on the central nervous system was evaluated by measurement of serum creatine kinase B-subunit (CKB) levels with use of radioimmunoassay in 58 patients who underwent computed tomographic (CT) scanning and 46 patients who underwent cerebral angiography for evaluation of cerebrovascular diseases, brain tumors, and other neurologic disorders. In 11 patients (10.6%), the CKB increased to abnormally high levels within 4 hours after the radiographic procedures, and the median value after 30 minutes was significantly higher than the corresponding precontrast value (P less than 0.01). Eight of the 11 patients had recent ischemic cerebrovascular diseases, and 7 of the 11 had undergone CT scanning. On the basis of the information available in the literature, elevation of the serum CKB levels may be interpreted as reflecting breakdown of the blood-brain barrier and neural damage. Intravascularly administered radiographic media are generally safe, but the results of the current investigation suggested the potential for detrimental effects, particularly in patients with recent cerebrovascular diseases.
D001921:Brain / Q000187:drug effects*; D001932:Brain Neoplasms / Q000097:blood / Q000000981:diagnostic imaging*; D002533:Cerebral Angiography; D002561:Cerebrovascular Disorders / Q000097:blood / Q000000981:diagnostic imaging*; D003287:Contrast Media / Q000009:adverse effects*; D003402:Creatine Kinase / Q000097:blood*; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D006801:Humans; D007482:Iothalamate Meglumine / Q000009:adverse effects; D007527:Isoenzymes; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D007527:Isoenzymes; D003974:Diatrizoate Meglumine; D003402:Creatine Kinase; D007482:Iothalamate Meglumine